The Role of CK7, S100A1, and CD82 (KAI1) Expression in the Differential Diagnosis of Chromophobe Renal Cell Carcinoma and Renal Oncocytoma

Characteristics of renal oncocytomas and clinical novelties: Single center experience of 17 years

Objective:

To assess the characteristics of renal oncocytomas and the clinical outcomes of patients in the last 17 years in our institution.

Methodology:

The medical records of the patients who underwent partial and radical nephrectomy from May 2004 to December 2021 were evaluated retrospectively. Radiology and pathology results were evaluated. Patients diagnosed with oncocytoma after surgery were included in the study.

Results:

Out of 791 patients who were operated for renal masses, 55 patients with the diagnosis of oncocytoma were included in the study, 17 of them were female. The mean age of the patients was 64.77 ± 10.58 years. Open and laparoscopic methods were applied to patients. Partial nephrectomy was performed in 25 patients (46.2%). It was observed that none of the patients with a mean follow-up of 76 months developed recurrence or death due to oncocytoma.

Conclusion:

Oncocytoma is a benign and rare tumor of the kidney which distinguishing it from malign tumors preoperatively with recent techniques is impossible. Especially in small sized tumors, considering the possibility of oncocytoma, nephron sparing surgery should be preferred in terms of patients’ benefit. Further research is needed for the novel imaging techniques and biomarkers proposed to be used in routine use to distinguish oncocytoma.

The Critical Gene Screening to Prevent Chromophobe Cell Renal Carcinoma Metastasis through TCGA and WGCNA

Common chromophobe renal cell carcinoma (chRCC) has a good prognosis when cured by surgery. However, clinical practice shows that a small number of patients with chRCC will produce metastasis, and the prognosis after metastasis is poor. In this regard, we try to find potential biological targets to prevent CRCC metastasis. In this experiment, we analyzed the clinical traits and gene expression data of chRCC samples which were provided by the TCGA database by the WGCNA method. On this basis, we selected MEtan, a module with a significant positive correlation with the M phase of chRCC, for subsequent analysis. The MEtan module genes in the biological process of chRCC were mainly related to steroid metabolic process, cholesterol metabolic process and STEM cell differentiation. KEGG analysis showed that these genes were mainly enriched in cancer-related signaling pathways, such as Neuroactive Ligand−receptor interaction, cAMP signaling pathway, and Wnt signaling pathway. Subsequently, we mapped the PPI interaction network and screened the key gene beta-arrestin 2 (ARRB2). Expression analysis showed that there was a significantly increased expression of ARRB2 in chRCC patients in comparison to the normal group. Expression survival analysis indicated that ARRB2 was inversely associated with overall survival. We firmly believe that the key genes identified in this study would be able to provide new clues and research basis for the treatment of chRCC.